• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA review sends BioMimetic shares plunging despite solid Q1 growth | Earnings roundup

FDA review sends BioMimetic shares plunging despite solid Q1 growth | Earnings roundup

May 12, 2011 By MassDevice staff

MassDevice.com Earnings Roundup

Shares of BioMimetic Therapeutics Inc. (NSDQ:BMTI) continued their slide today after plummeting 35.3 percent yesterday to close at $8.66 on news of the FDA’s dim view of its Augment bone graft product.

BMTI shares today recovered some of those losses to close at $9.20, up more than 6 percent for the day, but the stock was trading at $13.39 as of the market’s close on May 9 — the day before the release of the Food & Drug Administration’s summary of the company’s pre-market approval application for Augment.

The federal watchdog agency said a clinical study of the product, which is used to stimulate bone growth in foot and ankle fusion procedures, showed that it was not as successful as grafts taken from patients’ own bones. The agency’s Orthopedic and Rehabilitation Devices panel is set to meet tomorrow for a public hearing, after which it will vote whether to recommend that the FDA approve the device.

Augment is a drug/device combination that uses a recombinant human platelet-derived growth factor called B homodimer (rhPDGF-BB) and a bioresorbable synthetic bone matrix called beta-tricalcium phosphate or β-TCP. Surgeons mixequal amounts of the substances in a surgical bowl and pack the mixture into a bone void. BioMimetic won Health Canada approval from Health Canada in November 2009 for midfoot, hindfoot and ankle fusion indications. Augment has only been used in IDE studies in the U.S.

The company posted its first-quarter results this week, reporting a revenue increase of 13.2 percent, to $399,000, for the three months ended March 31. BioMimetic also shaved its net loss 6.7 percent, from $8.5 million during Q2 2010 to $8.0 million during the just-ended quarter.

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Bioject losses ease after sales bump
Bioject Medical Technologies Inc. (OTC:BJCT) posted a loss of $182,000, or 1 cent per diluted share, on sales of $1.7 million during the three months ended March 31. That compares with a loss of $568,000, or 3 cents per diluted share, on sales of $1.2 million during the same period last year.
Read more

Derma Sciences earnings stagnant despite increased sales
Derma Sciences Inc. (NSDQ:DSCI) posted a loss of $547,032, or 8 cents per diluted share, on revenue of $14.4 million during the three months ended March 31. That compares with a loss of $578,689, or 10 cents per diluted share, on revenue of $12.8 million during the same period last year.
Read more

DJO Global losses ease by more than a third
DJO Global Inc. reported a loss of $20.9 million on sales of $249.7 million during the three months ended April 2. That compares with a loss of $33.3 million on sales of $240.1 million during the same period last year.
Read more

pSivida losses remain unchanged
pSivida Corp. (NSDQ:PSDV) reported a loss of $2.7 million, or 13 cents per diluted share, on revenue of $360,000 during the three months ended March 31. That compares with a loss of $2.7 million, or 15 cents per diluted share, on revenue of $515,000 during the same period last year.
Read more

Cardica losses widen as sales remain unchanged
Cardica Inc. (NSDQ:CRDC) posted a loss of $3.6 million, or 14 cents per diluted share, on sales of $954,000 during the three months ended March 31. That compares with a loss of $3.0 million, or 12 cents per diluted share, on sales of $979,000 during the same period last year.
Read more

Misonix reports mixed Q1
Misonix Inc. (NSDQ:MSON) posted losses of $531,478, or 8 cents per diluted share, on revenue of $3.6 million during the three months ended March 31. That compares a loss of $281,492, or 4 cents per diluted share, on revenue of $3.3 million during the same period last year.
Read more

American Shared Hospital Services sales see small bump
American Shared Hospital Services (NSDQ:AMS) reported profits of $21,000, or 0 cents per diluted share, on sales of $4.4 million during the three months ended March 31. That compares with profits of $8,000, or 0 cents per diluted share, on sales of $4.1 million during the same period last year.

Tornier losses widen dramatically despite increased sales
Tornier N.V. (NSDQ:TRNX) posted a loss of $24.0 million, or 68 cents per diluted share, on sales of $69.4 million during the three months ended April 3. That compares with a loss of $10.0 million, or 41 cents per diluted share, on sales of $61.8 million during the same period last year.
Read more

Mindray sales rise 24 percent
Mindray Medical International Ltd. (NYSE:MR) posted profits of $37.7 million, or 32 cents per diluted share, on revenue of $180.9 million during the three months ended March 31. That compares with profits of $36.2 million, or 31 cents per diluted share, on revenue of $145.8 million during the same period last year.
Read more

Allied Healthcare Products sales slacken slightly
Allied Healthcare Products (NSDQ:AHPI) reported profits of $60,324, or 1 cent per share, on revenue of $11.3 million during the three months ended March 31. That compares with profits of $37,530, or 0 cents per share, on revenue of $11.6 million during the same period last year.
Read more

Luminex sales increase 30 percent
Luminex Corp. (NSDQ:LMNX) posted a profit of $4.5 million, or 11 cents per diluted share, on sales of $43.3 million during the three months ended March 31. That compares with a profit of $1.9 million, or 5 cents per diluted share, on sales of $33.3 million during the same period last year.
Read more

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: Allied Healthcare Products, American Shared Hospital Services, Bioject Medical Technologies Inc., BioMimetic Therapeutics Inc., Derma Sciences Inc., dextera, DJO Global, Luminex Corp., Mindray Medical International Ltd., pSivida Corp., Q1

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy